Newsletter Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.

Kiora Pharmaceuticals secures a patent for KIO-104, enhancing treatment options for ocular diseases and extending market exclusivity until 2043.

OpenAI's ChatGPT-4o enhances ophthalmological image generation, producing realistic retinal photographs while highlighting the need for further research in training datasets.

Ocular Therapeutix to showcase its drug delivery solutions at upcoming ophthalmology conferences.

Modern Retina provides ophthalmology professionals with the latest advancements, research, and expert insights in retinal ...

Sanofi's SAR446597 receives FDA fast track designation, offering a promising one-time gene therapy for geographic atrophy and reducing treatment frequency.

Advertorial: Could targeting retinal non-perfusion be the key to achieving true disease modification in diabetic retinopathy? The triad of inflammation, neuropathy, and vasculopathy plays a key role ...

The completion of the full BLA submission is anticipated in early 2026 and is eligible for priority review under the program’s fast-track designation.

Boehringer Ingelheim initiates THULITE study, exploring an oral treatment for diabetic macular edema, aimed to improve patient care and convenience.

Nanoscope Therapeutics establishes a Vision Advisory Committee to enhance retinal care and drive innovative therapies for vision restoration.